The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure

Several prognostic scoring systems have been developed to risk stratify patients with myelodysplastic syndromes (MDS) in order to serve as clinical decision tools. Such models include: the International Prognostic Scoring System (IPSS),[1][1] the World Health Organization (WHO) classification-based